Home
>
US Stocks
>
Medpace Holdings, Inc.

Medpace Holdings, Inc. (MEDP)

$208.23

+4.68

(+2.3%)▲

Live

Insights on Medpace Holdings, Inc.

  • Increasing Revenue

    Revenue is up for the last 12 quarters, 204.99M → 434.07M (in $), with an average increase of 6.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 4 quarters, 49.36M → 72.89M (in $), with an average increase of 11.6% per quarter

Performance

  • $204.16
    $208.56
    $208.23
    downward going graph

    1.95%

    Downside

    Day's Volatility :2.11%

    Upside

    0.16%

    downward going graph
  • $130.79
    $241.48
    $208.23
    downward going graph

    37.19%

    Downside

    52 Weeks Volatility :45.84%

    Upside

    13.77%

    downward going graph

Returns

PeriodMedpace Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
4.99%
0.3%
-6.7%
6 Months
-3.02%
-8.3%
-6.2%
1 Year
42.1%
-4.8%
-6.3%
3 Years
127.13%
23.8%
26.9%

Highlights

Market Capitalization
6.2B
Book Value
$11.37
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
7.92
PE Ratio
25.7
PEG Ratio
1.97
Wall Street Target Price
224.75
Profit Margin
16.44%
Operating Margin TTM
19.24%
Return On Assets TTM
13.72%
Return On Equity TTM
53.97%
Revenue TTM
1.6B
Revenue Per Share TTM
49.76
Quarterly Revenue Growth YOY
31.2%
Gross Profit TTM
925.1M
EBITDA
323.9M
Diluted Eps TTM
7.92
Quarterly Earnings Growth YOY
0.34
EPS Estimate Current Year
8.2
EPS Estimate Next Year
9.35
EPS Estimate Current Quarter
1.8
EPS Estimate Next Quarter
1.83

Analyst Recommendation

Buy
    54%Buy
    45%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Medpace Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
5
5
5
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 7.93%

Current $208.23
Target $224.75

Company Financials

FY17Y/Y Change
Revenue
436.2M
↑ 3.46%
Net Income
39.1M
↑ 191.41%
Net Profit Margin
8.97%
↑ 5.79%
FY18Y/Y Change
Revenue
704.6M
↑ 61.55%
Net Income
73.2M
↑ 87.07%
Net Profit Margin
10.39%
↑ 1.42%
FY19Y/Y Change
Revenue
861.0M
↑ 22.19%
Net Income
100.4M
↑ 37.25%
Net Profit Margin
11.67%
↑ 1.28%
FY20Y/Y Change
Revenue
925.9M
↑ 7.54%
Net Income
145.4M
↑ 44.74%
Net Profit Margin
15.7%
↑ 4.03%
FY21Y/Y Change
Revenue
1.1B
↑ 23.38%
Net Income
181.8M
↑ 25.08%
Net Profit Margin
15.92%
↑ 0.22%
FY22Y/Y Change
Revenue
1.5B
↑ 27.8%
Net Income
245.4M
↑ 34.93%
Net Profit Margin
16.81%
↑ 0.89%
Q4 FY21Q/Q Change
Revenue
308.6M
↑ 4.39%
Net Income
50.0M
↑ 3.01%
Net Profit Margin
16.22%
↓ 0.21%
Q1 FY22Q/Q Change
Revenue
330.9M
↑ 7.26%
Net Income
61.3M
↑ 22.54%
Net Profit Margin
18.53%
↑ 2.31%
Q2 FY22Q/Q Change
Revenue
351.2M
↑ 6.12%
Net Income
49.4M
↓ 19.49%
Net Profit Margin
14.05%
↓ 4.48%
Q3 FY22Q/Q Change
Revenue
383.7M
↑ 9.26%
Net Income
66.0M
↑ 33.77%
Net Profit Margin
17.21%
↑ 3.16%
Q4 FY22Q/Q Change
Revenue
394.1M
↑ 2.7%
Net Income
68.7M
↑ 4.0%
Net Profit Margin
17.42%
↑ 0.21%
Q1 FY23Q/Q Change
Revenue
434.1M
↑ 10.14%
Net Income
72.9M
↑ 6.15%
Net Profit Margin
16.79%
↓ 0.63%
FY17Y/Y Change
Total Assets
950.7M
↓ 2.9%
Total Liabilities
447.2M
↑ 21.39%
FY18Y/Y Change
Total Assets
967.9M
↑ 1.81%
Total Liabilities
378.2M
↓ 15.42%
FY19Y/Y Change
Total Assets
1.1B
↑ 18.09%
Total Liabilities
416.8M
↑ 10.19%
FY20Y/Y Change
Total Assets
1.4B
↑ 21.66%
Total Liabilities
584.9M
↑ 40.33%
FY21Y/Y Change
Total Assets
1.7B
↑ 19.36%
Total Liabilities
707.0M
↑ 20.88%
FY22Y/Y Change
Total Assets
1.4B
↓ 18.52%
Total Liabilities
966.1M
↑ 36.65%
Q4 FY21Q/Q Change
Total Assets
1.7B
↑ 5.25%
Total Liabilities
707.0M
↑ 4.12%
Q1 FY22Q/Q Change
Total Assets
1.3B
↓ 19.01%
Total Liabilities
739.3M
↑ 4.57%
Q2 FY22Q/Q Change
Total Assets
1.3B
↓ 2.15%
Total Liabilities
1.0B
↑ 39.61%
Q3 FY22Q/Q Change
Total Assets
1.3B
↑ 0.99%
Total Liabilities
978.5M
↓ 5.2%
Q4 FY22Q/Q Change
Total Assets
1.4B
↑ 1.81%
Total Liabilities
966.1M
↓ 1.27%
Q1 FY23Q/Q Change
Total Assets
1.4B
↑ 3.2%
Total Liabilities
1.0B
↑ 8.52%
FY17Y/Y Change
Operating Cash Flow
97.4M
↑ 6.16%
Investing Cash Flow
-12.2M
↓ 8.83%
Financing Cash Flow
-97.8M
↑ 68.65%
FY18Y/Y Change
Operating Cash Flow
156.6M
↑ 60.79%
Investing Cash Flow
-17.0M
↑ 38.7%
Financing Cash Flow
-141.6M
↑ 44.72%
FY19Y/Y Change
Operating Cash Flow
201.9M
↑ 28.92%
Investing Cash Flow
-19.1M
↑ 12.79%
Financing Cash Flow
-73.9M
↓ 47.79%
FY20Y/Y Change
Operating Cash Flow
258.7M
↑ 28.14%
Investing Cash Flow
-31.2M
↑ 63.05%
Financing Cash Flow
-82.3M
↑ 11.32%
FY21Y/Y Change
Operating Cash Flow
263.3M
↑ 1.8%
Investing Cash Flow
-31.4M
↑ 0.48%
Financing Cash Flow
-44.5M
↓ 45.97%
Q4 FY21Q/Q Change
Operating Cash Flow
70.9M
↓ 2.02%
Investing Cash Flow
-9.1M
↑ 38.12%
Financing Cash Flow
2.4M
↓ 146.69%
Q1 FY22Q/Q Change
Operating Cash Flow
46.3M
↓ 34.75%
Investing Cash Flow
-11.2M
↑ 22.95%
Financing Cash Flow
-412.1M
↓ 17051.17%
Q2 FY22Q/Q Change
Operating Cash Flow
96.6M
↑ 108.88%
Investing Cash Flow
-11.1M
↓ 0.72%
Financing Cash Flow
-123.5M
↓ 70.04%
Q3 FY22Q/Q Change
Operating Cash Flow
108.5M
↑ 12.29%
Investing Cash Flow
-7.2M
↓ 35.41%
Financing Cash Flow
-109.1M
↓ 11.63%

Technicals Summary

Sell

Neutral

Buy

Medpace Holdings, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Medpace Holdings, Inc.
Medpace Holdings, Inc.
-1.42%
-3.02%
42.1%
127.13%
383.15%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
-4.22%
10.11%
19.74%
50.21%
124.29%
Agilent Technologies Inc.
Agilent Technologies Inc.
-11.51%
-22.3%
-5.6%
33.93%
92.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-4.83%
-6.82%
-8.03%
49.43%
147.46%
Danaher Corp.
Danaher Corp.
-3.94%
-15.07%
-11.98%
40.41%
129.34%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
4.97%
-8.52%
-7.34%
33.49%
98.5%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Medpace Holdings, Inc.
Medpace Holdings, Inc.
25.7
25.7
1.97
8.2
0.54
0.14
0.0
11.37
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
55.23
55.23
7.21
9.69
0.94
0.22
0.0
10.13
Agilent Technologies Inc.
Agilent Technologies Inc.
26.91
26.91
2.36
5.63
0.25
0.1
0.01
18.96
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
34.01
34.01
4.28
23.68
0.14
0.05
0.0
109.55
Danaher Corp.
Danaher Corp.
25.0
25.0
3.24
8.74
0.14
0.06
0.0
68.31
IQVIA Holdings Inc.
IQVIA Holdings Inc.
35.62
35.62
1.48
10.42
0.18
0.05
0.0
31.98
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Medpace Holdings, Inc.
Medpace Holdings, Inc.
Buy
$6.2B
383.15%
25.7
16.44%
IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc.
Buy
$38.9B
124.29%
55.23
20.38%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$35.3B
92.09%
26.91
19.09%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$201.4B
147.46%
34.01
13.75%
Danaher Corp.
Danaher Corp.
Buy
$171.3B
129.34%
25.0
22.4%
IQVIA Holdings Inc.
IQVIA Holdings Inc.
Buy
$37.0B
98.5%
35.62
7.28%

Institutional Holdings

  • BlackRock Inc

    10.37%

  • Vanguard Group Inc

    8.72%

  • Wasatch Advisors Inc.

    6.09%

  • Fuller & Thaler Asset Management Inc

    3.08%

  • State Street Corporation

    2.76%

  • Amvescap Plc.

    1.94%

Company Information

Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages regulatory and therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 3,400 people across 37 countries.

Organization
Medpace Holdings, Inc.
Employees
5400
CEO
Dr. August James Troendle M.D.
Industry
Commercial Services

Discover More

FAQs